Roche Receives EMA CHMP Recommendation For Approval Of Macular Degeneration Treatment Susvimo

ROCHE HOLDINGS AG

ROCHE HOLDINGS AG

RHHBY

0.00
  • Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMD
  • Positive recommendation is based on data from the LADDER, Archway and Portal studies showing Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections1-3
  • By continuously delivering medicine into the eye through the Contivue® refillable implant, Susvimo may help people with nAMD maintain their vision with as few as two treatments per year1-3
  • nAMD is a leading cause of blindness in people over the age of 60 and affects 1.7 million in the European Union (EU)4
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.